Hot Flashes Clinical Trial
— STARTOfficial title:
STrength and AeRobic Training Against Vasomotor Symptoms (START) in Postmenopausal Women
The goal of this randomised controlled trial is to investigate the effects of and compare two modes of physical exercise (strength training and high-intensity aerobic exercise) to unchanged physical activity on vasomotor symptoms (hot flushes) in postmenopausal women. The main question it aims to answer is the effect of 15 weeks of strength training vs high intensity aerobic training vs unchanged physical activity on frequency and severity of hot flushes. Participants will be randomised to: 1. strength training 2. high-intensity aerobic training 3. untreated control group. Researchers will compare strength training, high-intensity aerobic training and untreated control group to see if training can reduce hot flushes.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | December 2032 |
Est. primary completion date | June 2027 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 45 Years and older |
Eligibility | Inclusion Criteria: - Postmenopausal women (one of: = 12 months since last menstruation; amenorrhea due to intrauterine device or hysterectomy and Follicle Stimulating Hormone (FSH) >30 mIU/ml; bilateral oophorectomy; induced menopause due to chemotherapy or radiation and =2 years amenorrhea); - = 28 moderate to severe hot flushes per week during a 2-week screening period, registered through a daily VMS diary; - Age =45 years; - Physical ability to participate in strength training or high intensity aerobic exercise for 60 minutes, 3 times/week during 15 weeks; - Understand Swedish orally and in writing Exclusion Criteria: - Regular physical activity >30 minutes per week of vigorous intensity or =150 minutes of moderate intensity or combined activities representing maximum 150 minutes of moderate intensity; - Use of systemic menopausal hormone therapy the last 2 months; - Use of natural preparations such as herbal preparations for VMS, or other medications for VMS the last 2 months; - Capillary hemoglobin <110 g/l; - Blood pressure >160 mmHg systolic or >100 mmHg diastolic; - Unstable medical condition with a potential to affect VMS (like unregulated thyroid disease); - Medical condition that by a physician is judged not appropriate (because of potential to affect VMS or risk of injury with vigorous exercise) |
Country | Name | City | State |
---|---|---|---|
Sweden | Region Kalmar Län | Kalmar | |
Sweden | Region Östergötland | Linköping |
Lead Sponsor | Collaborator |
---|---|
Linkoeping University | Länssjukhuset i Kalmar län, Region Östergötland |
Sweden,
Berin E, Hammar M, Lindblom H, Lindh-Astrand L, Ruber M, Spetz Holm AC. Resistance training for hot flushes in postmenopausal women: A randomised controlled trial. Maturitas. 2019 Aug;126:55-60. doi: 10.1016/j.maturitas.2019.05.005. Epub 2019 May 14. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of moderate and severe hot flushes | Frequency of hot flushes per 24 h daily recorded in hot flush diary from baseline throughout 15 weeks of intervention. | baseline to 15 weeks | |
Secondary | Frequency of moderate and severe hot flushes | Frequency of hot flushes per 24 h daily recorded in hot flush diary 2 weeks at baseline and 2 weeks at each of the time points. | baseline to 6 months, 1, 2 and 5 years | |
Secondary | Severity of hot flushes | Severity of hot flushes per 24 hours recorded in hot flush diary from baseline throughout 15 weeks of intervention and two weeks during follow-up. | baseline to 15 weeks, 6 months, 1, 2 and 5 years | |
Secondary | Generic health-related quality of life | Short-form 36, 36 questions in 8 scales. Scores for each domain range from 0-100, and a high score represents a higher health-related quality of life. | baseline to 15 weeks, 6 months, 1, 2 and 5 years after intervention | |
Secondary | Women specific health-related quality of life | Women's health questionnaire nine sub-scales with four-point scales (yes definitely, yes sometimes, not not much, no not at all) that are reduced to binary options (0/1). The subscale items are summated and divided by the number of items in each subscale.A higher score represents worse outcome. | baseline to 15 weeks, 6 months, 1, 2 and 5 years after intervention | |
Secondary | Physical activity levels | International Physical Activity Questionnaire short form, the participant describes the amount of time (minutes and hours) that is spent on different physical activities each week, the more time, the better, except for the question about the amount of time spent in sitting. | baseline to 15 weeks, 6 months, 1, 2 and 5 years after intervention | |
Secondary | Sleep quality | Pittsburgh sleep quality index, 7 domains. For the total instrument, the lower score, the better, from 0 (best) to 21 (worst). | baseline to 15 weeks, 6 months, 1, 2 and 5 years after intervention | |
Secondary | Diet | Bespoke questionnaire, primarily to control for changes during the intervention period. Registration of amounts or portions. Results are presented question by question descriptively. | baseline to 15 weeks, 6 months, 1, 2 and 5 years | |
Secondary | Accomplished physical activity | Bespoke training diary | baseline to 15 weeks, 6 months, 1, 2 and 5 years after intervention | |
Secondary | Bioimpedance | Fat mass (%) and fat-free (muscle) mass (%) | baseline to 15 weeks | |
Secondary | Weight | kilogram (kg) | baseline to 15 weeks | |
Secondary | Lenght | meters (m) | baseline to 15 weeks | |
Secondary | Body mass index | kilograms/meters2 (kg/m2) | baseline to 15 weeks | |
Secondary | Waist circumference | millimeters (mm) | baseline to 15 weeks | |
Secondary | Systolic and diastolic blood pressure | Unit millimetre of mercury (mmHg) | baseline to 15 weeks | |
Secondary | Hematologic and ironstatus changes | Hemoglobin full body count, Transferrin(gram/Litre), and Ferritin (microgram/Litre) | baseline to 15 weeks, and 1 year | |
Secondary | Changes in blood-lipids | apolipoprotein A1, apolipoprotein B (gram/Litre) and total cholesterol, low-density lipoprotein, high-density lipoprotein (mmol/L) and leptin (ng/mL) | baseline to 15 weeks, and 1 year | |
Secondary | Changes in sex hormones and gonadotrophins | Estradiol (pmol/Litre), Sex hormone bindning globulin, Testosterone (nmol/Litre), follicle-stimulating hormone, luteinizing hormone (IE/Litre) | baseline to 15 weeks, and 1 year | |
Secondary | Changes in glucose profile | HbA1c (mmol/Litre) and fasting blood glucose (mmol/L) | baseline to 15 weeks, and 1 year | |
Secondary | Changes in inflammatory biomarkers | high-sensitive C-reactive Protein (microgram/Litre), Brain-derived neutrophic factor, Matrix metalloproteinase-2 and -9 (ng/mL), Interleukin -4, -6, -7, -8, 10, -15, tumour necrosis factor, monocyte chemoattractant protein-1 (pg/mL) | baseline to 15 weeks, and 1 year | |
Secondary | Changes in the lenght of telomeres in white blood cells | Telomeres (kilobase) pair | baseline to 15 weeks, and 1 year | |
Secondary | Change in exercise capacity | Change in exercise capacity is primarily used as a measure of adherence and obtained through cardiopulmonary exercise testing assessing maximum oxygen uptake milliliter/kilogram/minute (ml/kg/minute) and analysed according to local clinical routines. | baseline to 15 weeks | |
Secondary | Experiences of the interventions, facilitators and barriers | Bespoke questionnaire, only for intervention groups. Results will be presented descriptively question by question. | baseline to 15 weeks | |
Secondary | Adherence to the interventions | Assessed through bespoke training diary where each training session is registered and the total number of training sessions as well as training sessions/week will be calculated. | baseline to 15 weeks | |
Secondary | Muscle strength | For strength training group only, measured using 8 repetition-maximum tests. | baseline to 15 weeks | |
Secondary | Adverse events | Adverse events of taking part in the study | baseline to 15 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04587154 -
Womens Study to Alleviate Vasomotor Symptoms
|
N/A | |
Terminated |
NCT03642119 -
Validation of an Objective Instrument to Measure Hot Flashes During Menopause
|
||
Completed |
NCT05061563 -
A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults
|
Phase 1 | |
Completed |
NCT05419908 -
Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes
|
Phase 2 | |
Completed |
NCT01281332 -
Mechanical Device for the Relief of Hot Flashes
|
Phase 2 | |
Completed |
NCT01439945 -
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
|
Phase 2 | |
Completed |
NCT00755417 -
Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT00599456 -
Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women.
|
N/A | |
Completed |
NCT01293695 -
Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial
|
N/A | |
Completed |
NCT00256685 -
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
|
Phase 3 | |
Completed |
NCT00391417 -
Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms
|
Phase 3 | |
Terminated |
NCT00244894 -
Acupuncture in Treating Hot Flashes in Patients With Prostate Cancer
|
N/A | |
Completed |
NCT00010712 -
Effects of Black Cohosh on Menopausal Hot Flashes
|
Phase 2 | |
Active, not recruiting |
NCT03580499 -
Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy
|
N/A | |
Recruiting |
NCT04418115 -
Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option?
|
N/A | |
Recruiting |
NCT04861701 -
Effect and Predictors for Hot Flush in Women Undergoing Static Stretching Exercise
|
N/A | |
Active, not recruiting |
NCT05086705 -
EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer
|
N/A | |
Completed |
NCT05099159 -
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
|
Phase 3 | |
Completed |
NCT01140646 -
Evaluation of SAMe for Hot Flashes
|
Phase 2 | |
Completed |
NCT00956813 -
Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy
|
Phase 3 |